Dominari (NASDAQ:DOMH) Rating Lowered to Sell at Wall Street Zen
by Amy Steele · The Cerbat GemDominari (NASDAQ:DOMH – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Separately, Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Dominari presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on Dominari
Dominari Price Performance
Shares of Dominari stock opened at $2.92 on Friday. The stock has a market cap of $66.02 million, a price-to-earnings ratio of -0.75 and a beta of 0.80. The firm’s 50-day moving average is $3.11 and its 200 day moving average is $4.21. Dominari has a 1 year low of $2.68 and a 1 year high of $8.40.
Hedge Funds Weigh In On Dominari
Hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC bought a new position in Dominari in the 4th quarter worth about $50,000. PFG Investments LLC bought a new position in Dominari during the 4th quarter valued at about $53,000. Price T Rowe Associates Inc. MD bought a new position in Dominari during the 4th quarter valued at about $96,000. Oxford Asset Management LLP bought a new position in Dominari during the 4th quarter valued at about $120,000. Finally, Jane Street Group LLC bought a new position in Dominari during the 2nd quarter valued at about $158,000. Institutional investors own 42.48% of the company’s stock.
About Dominari
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.